Redwood City, CA — Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that the Patent Trial and Appeals Board (PTAB) at the U.S. Patent and Trademark Office (USPTO) has denied instituting an inter partes review (IPR) of U.S. Patent No. 8,359,102 (the ‘102 patent).
On May 14, 2015, a unit of Boston Scientific Corporation filed two petitions challenging the validity of certain claims of the ‘102 patent. In its written decision, however, the PTAB determined that Boston Scientific failed to establish a reasonable likelihood of showing that even one of the challenged claims of the ‘102 patent was invalid, and that therefore both petitions were denied.
“The PTAB’s decision reaffirms the validity of our IP position and our ability to protect our innovations in the neuromodulation field,” says Nevro’s CEO Michael DeMane.
The ‘102 patent is one of Nevro’s 56 issued U.S. patents directed to Nevro’s innovations in the neuromodulation field.
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro’s proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.